Early Tests Show Nivolumab Triples Life Expectancy in Patients With Lung Cancer

Published: Tuesday, Jun 13, 2017

An early round of clinical testing shows that users of Opdivo, a drug sanctioned for treatment of small-cell lung cancer, more than tripled their five-year survival rate beyond the statistical average.

Opdivo maker Bristol-Myers Squibb Co. announced the findings April 3 during an annual meeting of the American Association for Cancer Research in Washington, D.C.

The study’s author was quoted in an announcement as saying typical survival rates measured over a five-year interval have hovered around 5 percent.

“We observe that the estimated five-year overall survival rate in Opdivo-treated patients in the study was 16 percent,” said Dr. Scott N. Gettinger, an associate professor of medicine at Yale Cancer Center in New Haven. “In addition, based on investigator assessments, the majority of these patients showed no evidence that their lung cancer had progressed at the time of their last follow-up.”

Read the full article by PatientDaily at http://patientdaily.com/stories/511101976-early-tests-show-opdivo-triples-life-expectancy-in-lung-cancer-patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x